Stockscreener 앱 받기
15.35
1.93%
0.29
시간 외 거래:
15.30
-0.05
-0.33%
전일 마감가:
$15.06
열려 있는:
$15.26
하루 거래량:
149.00K
Relative Volume:
1.66
시가총액:
$408.02M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.72%
1개월 성능:
+16.46%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$15.03
$16.20
1주일 범위
$13.68
$16.20
52주 변동 폭
$11.81
$16.20
Carlsmed Inc Stock (CARL) Company Profile
명칭
Carlsmed Inc
전화
858-295-9290
주소
1800 ASTON AVENUE, CARLSBAD
CARL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
15.35 | 400.31M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
279.08 | 45.01B | 2.97B | 809.93M | 1.33B | 4.87 |
|
TEM
Tempus Ai Inc
|
87.07 | 15.02B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
73.60 | 13.61B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
95.59 | 7.95B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
38.58 | 6.72B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-18 | 개시 | BTIG Research | Buy |
| 2025-08-18 | 개시 | BofA Securities | Buy |
| 2025-08-18 | 개시 | Goldman | Buy |
| 2025-08-18 | 개시 | Piper Sandler | Overweight |
| 2025-08-18 | 개시 | Truist | Buy |
Carlsmed Inc 주식(CARL)의 최신 뉴스
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Two AI Small Caps Nobody Noticed - Nanalyze
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest
Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha
BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener
This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener
Carlsmed initiated with a Buy at BTIG - TipRanks
Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com
Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener
Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech By Investing.com - Investing.com South Africa
Carlsmed initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Carlsmed stock with Overweight rating on custom implant potential - Investing.com India
Goldman Sachs initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Canada
Goldman Sachs initiates coverage on Carlsmed stock with Buy rating - Investing.com
Carlsmed initiated with a Buy at Goldman Sachs - MSN
Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish - Stocktwits
Carlsmed, Inc. shares fall 2.01% after-hours as it prepares to report Q2 2025 financial results. - AInvest
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025 - The Manila Times
Carlsmed to report Q2 2025 financial results on Aug 28, 2025. - AInvest
Big Boost for Personalized Cervical Fusion: Add-On Code - Orthopedics This Week
Carlsmed Inc (CARL) 재무 분석
Carlsmed Inc (CARL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Carlsmed Inc 주식 (CARL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sidow Kevin | Director |
Jul 24 '25 |
Buy |
15.00 |
13,333 |
199,995 |
59,566 |
| Mittendorff Robert II | Director |
Jul 24 '25 |
Buy |
15.00 |
1,333,333 |
19,999,995 |
5,013,839 |
| ROOT JONATHAN D | Director |
Jul 24 '25 |
Buy |
15.00 |
466,666 |
6,999,990 |
483,999 |
| YOUNG PHILIP M | Director |
Jul 24 '25 |
Buy |
15.00 |
59,999 |
899,985 |
53,333 |
2.43%
0.60%
자본화:
|
볼륨(24시간):